Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.

Alan Bonder, MD, and Kris Kowdley, MD, discuss unmet patient needs, pruritus assessment tools, and guideline-based therapy provided by an interprofessional care team. They also explore safety and efficacy data from trials of emerging treatment options including ileal bile acid transporter (IBAT) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists.